LIMITED OFFER
Save 50% on book bundles
Immediately download your ebook while waiting for your print delivery. No promo code needed.
Natural Products
- 1st Edition, Volume 61 - November 15, 2023
- Editor: Karl Heinz Altmann
- Language: English
- Hardback ISBN:9 7 8 - 0 - 4 4 3 - 1 3 7 0 9 - 9
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 1 3 7 1 0 - 5
Natural Products, Volume 61 in the Annual Reports in Medicinal Chemistry series, highlights new advances in the field, with this new volume presenting interesting chapters on C… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteNatural Products, Volume 61 in the Annual Reports in Medicinal Chemistry series, highlights new advances in the field, with this new volume presenting interesting chapters on Chemical evolution of natural product structure for drug discovery, Fungal Metabolites, Polypharmacology of Natural Products, Glycopeptide Antibiotics, and Natural products-based drug discovery for the CNS.
- Provides the authority and expertise of leading contributors from an international board of authors
- Presents the latest release in the Annual Reports in Medicinal Chemistry serials
- Updated release includes the latest information on Natural Products
Undergraduates, graduates, academics, and researchers in the field of medicinal chemistry
- Cover image
- Title page
- Table of Contents
- Series Page
- Copyright
- Contributors
- Preface
- Chapter One Chemical evolution of natural product structure for drug discovery
- Abstract
- 1 Introduction
- 2 Pseudo-natural product design principle
- 3 Synthesis and biological evaluation of pseudo-NPs
- 4 Cheminformatic analysis
- 5 Conclusions and outlook
- Acknowledgments
- References
- Chapter Two The polypharmacology of natural products in drug discovery and development
- Abstract
- 1 Introduction
- 2 What is polypharmacology?
- 3 Are natural products more likely to be multi-targeting as compared to synthetic drugs?
- 4 The possible mechanisms of polypharmacology in natural products
- 5 Case studies of the polypharmacology of selected natural products
- 6 The outliers: Natural products with little to no known biological activities to date
- 7 Conclusion
- References
- Chapter Three Pharmacology of marine drugs: Pattern-, purpose- and prudence-driven innovations
- Abstract
- 1 Introduction
- 2 The last 5 years (2019–2023)
- 3 Perspectives: Is there still room for more?
- References
- Chapter Four Advances in natural products driven drug discovery from medicinal plants for neuropathic pain
- Abstract
- 1 Introduction
- 2 Comorbidities associated with neuropathic pain
- 3 Mechanisms of neuropathic pain
- 4 Distinct pattern of action of different pain therapeutics
- 5 Secondary metabolites (natural products) of medicinal plants acting as anti-neuropathic agents
- 6 Clinical perspective array of pain therapeutics
- 7 Conclusion
- References
- Chapter Five Targeting the bacterial β-sliding clamp (DnaN): A promising strategy for novel antibiotics
- Abstract
- 1 Bacterial β-sliding clamp (DnaN)
- 2 Known bacterial DnaN inhibitors
- 3 Methods of studying DnaN binding and inhibition of DNA replication
- 4 Summary and perspectives
- References
- No. of pages: 310
- Language: English
- Edition: 1
- Volume: 61
- Published: November 15, 2023
- Imprint: Academic Press
- Hardback ISBN: 9780443137099
- eBook ISBN: 9780443137105
KA
Karl Heinz Altmann
Karl-Heinz Altmann has been Professor of Pharmaceutical Biology at the Institute of Pharmaceutical Sciences at the ETH Zurich since July 1st, 2003.
Professor Altmann was born in 1957 in Hochheim/Main, Germany. He studied chemistry at the Johannes-Gutenberg University in Mainz, from where he graduated with a diploma in 1983. His subsequent Ph. D. work in the area of peptide chemistry was performed at the University of Basel from 1984-1986. Karl-Heinz Altman then spent two and a half years as a post-doctoral associate at Cornell University, Ithaca, NY, which was followed by a one year stay as a master assistant at the University of Lausanne. In Sept. 1990 Karl-Heinz Altmann joined Ciba-Geigy's Central Research Laboratories in Basel, where he worked on the design and synthesis of modified nucleosides as potential building blocks for antisense therapeutics until 1996. In 1997 he moved to Oncology Research within Novartis Pharma AG, which had been formed through the merger between Sandoz and Ciba-Geigy. After four years as a project leader in Oncology Research Karl-Heinz Altmann was appointed the Novartis Senior Chemistry Expert in 2000. From Jan. 2003 until his move to the ETH, he was the acting Global Head of Chemistry of the Novartis Institutes for BioMedical Research (NIBR).
Prof. Altmann's research interests are at the interface between chemistry and biology, with a particular focus on the chemical synthesis and the biological and pharmacological profiling of biologically active natural products and their synthetic and semi-synthetic analogs. This research on one hand aims at the understanding of the mechanism of action of such molecules and the elucidation of the structural requirements for biological activity. On the other hand, it tries to assess the therapeutic potential of such compounds with the ultimate goal to discover new therapeutics for clinical applications.
In 1998, he received the "Novartis Leading Scientist Award", an important internal science award of Novartis Pharma AG.
In 2014, he was awarded the Paul-Ehrlich Prize of the Société Chimie Thérapeutique, France.
In 2017, he co-founded Tolremo Therapeutics AG, together with Dr. Stefanie Flückiger-Mangual, the late Prof. Wilhelm Krek, Dr. Isaac Kobrin, and Emmanuel Savioz.
Affiliations and expertise
Professor of Pharmaceutical Biology, Institute of Pharmaceutical Sciences, ETH Zurich, SwitzerlandRead Natural Products on ScienceDirect